Drug intelligence / Profile preview

PLGAI-003

Development stage: Preclinical
Lead developer: Peptilogics
Modality: Small Molecules, Peptides

Overview

PLGAI-003 is a synthetic peptide-based investigational therapeutic developed by Peptilogics for the treatment of cancer (neoplasms). It is classified as an antineoplastic agent and peptide. The drug is being designed using Peptilogics' AI-driven platform Nautilus to explore novel chemical design spaces for biologically viable and scalable peptide therapeutics. As of March 2025, its mechanism of action remains undefined or undisclosed in public sources. The compound is considered a new molecular entity and has not yet entered clinical trials; it remains in the discovery or early research phase[1][2][4].

Beyond the preview

Go deeper on PLGAI-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLGAI-003.

Explore the full profile